UNI-EN 192:Optimization of the activity in foreign markets
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 192 | / | 2023 | |||||||
| Date of issue: | 2023-10-16 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Optimization of the activity in foreign markets | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| “Sopharma” AD (the Company) notifies that in fulfillment of the goals for optimization of the foreign markets activities, the functions of the representative office of "Sopharma" AD in Russia will be taken over by the newly established subsidiary "Sopharma Rus" EOOD. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_2023_Sopharma_Rus_espi.pdf SFA_2023_Sopharma_Rus_espi.pdf | Optimization of the activity in foreign markets | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2023-10-16 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 16.6 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
